Nuclear Medicine: Radioactivity for Diagnosis and Therapy - Paperback
$40.99
$54.99
-25%Quantity
01
Pay over time for orders over $35.00 with
Offers & Perks
Earn 40 points with this purchase
Added to your rewards balance after checkout.
100 points welcome bonus
Create an account and start with extra points.
Languages:EnglishPublisher:EDP SciencesISBN-13:9782759821402ISBN-10:2759821404UPC:9782759821402Book Category:Medical, ScienceBook Subcategory:Allied Health Services, Physics, Radiology, Radiotherapy & Nuclear MedicineBook Topic:Imaging Technologies, NuclearSize:8.25 x 5.50 x 0.59 inchesWeight:0.3Product ID:SCMPWDT1PD
No detailed description available for "Nuclear medicine".
Languages:EnglishPublisher:EDP SciencesISBN-13:9782759821402ISBN-10:2759821404UPC:9782759821402Book Category:Medical, ScienceBook Subcategory:Allied Health Services, Physics, Radiology, Radiotherapy & Nuclear MedicineBook Topic:Imaging Technologies, NuclearSize:8.25 x 5.50 x 0.59 inchesWeight:0.3Product ID:SCMPWDT1PD
Contributor: Richard Zimmermann Richard Zimmermann est chimiste, Docteur en sciences physique. Il s'est spécialisé en pharmacologie moléculaire. Après une carrière de recherche, il est désormais le Directeur des projets TEP Europe (Tomographie à émission de positons) au sein de CISBio-Shering. (au moment de la parution de l'ouvrage)
RICHARD ZIMMERMANN has spent fifteen years in the research departments of conventional pharmaceutical industries based in France, Germany, and the Netherlands, in fields such as cardiology, immunology, and gastroenterology. Since 1999, he has been actively involved in the industrial nuclear medicine field. He started as Head of Research and Development at Saclay, France; he then became Head of PET Business Europe, and was later appointed Head of Business
Development for a large radiopharmaceutical group. He has been an independent consultant since 2012 (Chrysalium Consulting); in addition, he is the chairman of two companies which are active in this field, and he is a board member and advisory board member of several other radiopharmaceutical companies. He has also initiated - and currently chairs - the Oncidium Foundation, aiming to promote radiotherapeutics.
-------------
RICHARD ZIMMERMANN has spent fifteen years in the research departments of conventional pharmaceutical industries based in France, Germany, and the Netherlands, in fields such as cardiology, immunology, and gastroenterology. Since 1999, he has been actively involved in the industrial nuclear medicine field. He started as Head of Research and Development at Saclay, France; he then became Head of PET Business Europe, and was later appointed Head of Business
Development for a large radiopharmaceutical group. He has been an independent consultant since 2012 (Chrysalium Consulting); in addition, he is the chairman of two companies which are active in this field, and he is a board member and advisory board member of several other radiopharmaceutical companies. He has also initiated - and currently chairs - the Oncidium Foundation, aiming to promote radiotherapeutics.
Publisher: EDP Sciences
Edition
2nd Edition
Contributor(s)
Author
Free shipping on orders over $75. Standard shipping takes 3-7 business days. Returns accepted within 30 days of purchase.